gip glp 1 agonist tirzepatide Bridging the gap between GLP1-receptor agonists and cardiovascular outcomes: evidence for the role of | Cardiovascular Diabetology Dual GIP/GLP-1 receptor agonists: New

10.1056/NEJMoa2413258

Disclaimer: This article is for educational purposes only and is not a substitute for medical advice

doi: 10.1016/j.neuropharm.2017.08.022 81 HuangJLiuYChengLLiJZhangTZhaoGet al

It is critical to understand the difference between compounded and brand-name GLP-1 medications: Brand-name medications (Wegovy, Zepbound) are FDA-approved, manufactured under strict quality controls, and have been tested in large-scale clinical trials Compounded versions are not FDA-approved, meaning they have not undergone the same safety and efficacy testing In 2025, the FDA declared the shortage over, meaning compounding of semaglutide and tirzepatide is no longer legally permitted for most pharmacies Some compounded products have used different salt forms of semaglutide (such as semaglutide acetate instead of semaglutide sodium) that have not been shown to behave identically in the body Who Is a Good Candidate for GLP-1 Weight Loss Medication

Avoid large drinks with meals

iScience 2021, 24